Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Human epidermal growth factor receptor 1 (HER1) and HER2 are key oncogenes and validated cancer therapy targets.
• Monospecific therapies face resistance due to HER family member upregulation.
• Combined therapies are explored to overcome resistance.

Purpose of the Study:

• To propose and evaluate a novel approach for simultaneous HER1 and HER2 inactivation using multi-epitope blockade via vaccination-induced polyclonal antibodies.
• To assess the efficacy of this approach in inhibiting tumor cell growth and down-signaling cascades.

Main Methods:

• Inducing polyclonal antibodies through vaccination targeting HER1 and HER2.
• Evaluating the antibodies' ability to impair receptor activation and induce degradation.
• Assessing the impact on down-signaling cascades, cell cycle, and apoptosis in human tumor cells.
• Testing the efficacy on tumor lines with varying HER1 and HER2 expression levels.

Main Results:

• Vaccination-induced antibodies effectively impaired HER1 and HER2 activation and promoted their degradation.
• Inhibition of down-signaling cascades led to cell cycle arrest and apoptosis in human tumor cells.
• Reduced tumor cell viability was observed, with greater efficacy in lines expressing lower levels of HER1 and HER2.

Conclusions:

• Simultaneous inactivation of HER1 and HER2 by multi-epitope blockade is a viable strategy.
• This approach shows potential for developing multivalent vaccines against cancer.
• These findings contribute to the rational design of novel cancer therapeutics targeting HER receptors.